The stock of Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) hit a new 52-week low and has $3.02 target or 12.00% below today’s $3.43 share price. The 8 months bearish chart indicates high risk for the $42.16M company. The 1-year low was reported on Oct, 7 by Barchart.com. If the $3.02 price target is reached, the company will be worth $5.06 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 20,394 shares traded hands. Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) has declined 13.50% since March 4, 2016 and is downtrending. It has underperformed by 21.54% the S&P500.
Analysts await Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) to report earnings on November, 10.
According to Zacks Investment Research, “Imprimis Pharmaceuticals, Inc. is a pharmaceutical company focused on its proprietary ophthalmology and urology drug formulations. Imprimis recently launched its urology business, which includes a patented formulation to address patients suffering from interstitial cystitis.”
Insitutional Activity: The institutional sentiment increased to 1.2 in 2016 Q2. Its up 0.06, from 1.14 in 2016Q1. The ratio increased, as 3 funds sold all Imprimis Pharmaceuticals Inc shares owned while 2 reduced positions. 1 funds bought stakes while 5 increased positions. They now own 1.66 million shares or 37.14% less from 2.64 million shares in 2016Q1.
Blackrock Fund has 32,979 shares for 0% of their US portfolio. Blackrock Investment Management Ltd Liability reported 1,966 shares or 0% of all its holdings. Moreover, Vanguard has 0% invested in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) for 168,584 shares. Creative Planning has 750 shares for 0% of their US portfolio. Marathon Mgmt has 0.05% invested in the company for 25,000 shares. The Massachusetts-based Geode Cap Management Lc has invested 0% in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY). Northern accumulated 43,667 shares or 0% of the stock. Granite Prtnrs Ltd Limited Liability Company reported 155,190 shares or 0.05% of all its holdings. Berson & Corrado Invest Advisors Lc holds 0.08% of its portfolio in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) for 31,107 shares. Opaleye Inc last reported 0.98% of its portfolio in the stock. Bard Assocs holds 0.13% of its portfolio in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) for 65,500 shares. Marathon Asset Mngmt Limited Partnership owns 833,333 shares or 0.17% of their US portfolio. Tower Research Capital Limited Liability (Trc) accumulated 548 shares or 0% of the stock. Manufacturers Life Insur Comm The holds 169 shares or 0% of its portfolio. Moreover, Pnc Gp has 0% invested in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) for 2,000 shares.
More notable recent Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) news were published by: Quotes.Wsj.com which released: “News Imprimis Pharmaceuticals Inc.IMMY” on February 08, 2013, also Prnewswire.com with their article: “Imprimis Pharmaceuticals Launches Imprimis Cares Access Network (ICAN) to …” published on September 06, 2016, Prnewswire.com published: “Imprimis Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year …” on March 03, 2016. More interesting news about Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) were released by: Prnewswire.com and their article: “Imprimis Pharmaceuticals Strengthens Senior Leadership Team with Key Hires in …” published on August 15, 2016 as well as Prnewswire.com‘s news article titled: “Imprimis Pharmaceuticals Signs License Agreement to Bring Proprietary …” with publication date: August 12, 2015.
IMMY Company Profile
Imprimis Pharmaceuticals, Inc. (Imprimis), incorporated on January 11, 2006, is engaged in the development, production and dispensing of compounded pharmaceuticals. The Firm operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Firm is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Firm also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas, including oncology, autoimmunity, chronic infectious diseases and endocrine and metabolic diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.